Last updated: July 28, 2025
Introduction
Patent WO2007099396, filed under the World Intellectual Property Organization (WIPO) system, pertains to a pharmaceutical invention with potential therapeutic applications, likely in the realm of small molecules or biologics. As part of ensuring strategic patent portfolio management and competitive intelligence, a comprehensive analysis of its scope, claims, and broader patent landscape is essential. This document provides an in-depth review, illuminating the inventive scope, key claims, and the patent environment surrounding the application.
Overview of WO2007099396
Claimed under PCT (Patent Cooperation Treaty), WO2007099396 was published in July 2007. The application, based on its abstract, relates to a novel chemical entity or a class of compounds exhibiting specific biological activity, possibly a pharmaceutical compound for treating a targeted disease. The invention encompasses pharmaceutical compositions, use claims, and methods of synthesis or formulation.
Its origin indicates a strategic effort to protect innovation early across multiple jurisdictions, potentially including priority filing details from national applications.
Scope of the Patent: Key Focus Areas
The patent’s scope hinges on the broadness and clarity of its claims, which define the legal boundaries of protection. The scope encompasses:
-
Chemical Composition and Structure: The claims likely cover a class of molecules sharing a core structure with specified substitutions, designed to exhibit desired activity. Patent claims often delineate substitution patterns, stereochemistry, and functional groups, which determine the chemical scope.
-
Therapeutic Application: Claims specify particular medical uses, such as treating a disease (e.g., cancer, neurological disorders). Use claims are critical in establishing method-of-use patent protection.
-
Pharmaceutical Formulations: The invention probably extends to formulations comprising the patented compounds, including dosage forms, carriers, and adjuvants.
-
Synthesis and Manufacturing: Claims may cover specific synthetic routes, intermediates, or processes optimized for producing the active compounds, thus broadening the invention’s scope to manufacturing methods.
-
Combination Therapies: The application might also include claims for combining the compound with other therapeutic agents, increasing the patent’s commercial scope.
Claims Analysis
Understanding the scope and strength of WO2007099396 depends on dissecting its claims, typically organized into independent and dependent claims.
1. Independent Composition Claims
These claims define the chemical compounds or classes thereof, often expressed as:
"A compound of Formula I or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof..."
Key considerations:
-
Structural Breadth: The claims often encompass a core scaffold with R1, R2, R3 substituents, and similar modifications. The breadth depends on how many variations are encompassed without overreach.
-
Functional Limitation: The claims specify biological activity (e.g., receptor binding, enzyme inhibition), tethering the chemical structure to its function.
-
Clarity and Definiteness: The chemical terms are precise; overly broad claims could be vulnerable to invalidation if they lack sufficient written description or enablement.
2. Use Claims
Methodology claims are directed toward:
"The use of compound [X] for the treatment of [disease]"
They significantly expand patent scope by covering therapeutic applications, which are especially valuable in drug patenting.
3. Formulation and Combination Claims
These specify:
- Pharmaceutical compositions comprising the compound and carriers.
- Methods of administering the compound alone or with other agents.
4. Process Claims
Claims related to synthesis routes, intermediates, or purification processes.
Patent Landscape Overview
The patent landscape for the technology area covered by WO2007099396 is characterized by:
-
Prior Art Search: Pre-2007, patent literature indicates numerous filings covering molecules with similar scaffolds, especially in the fields of kinase inhibitors, receptor modulators, or neuroprotective agents.
-
Patent Families and Related Applications: Several patents are likely related, either directly citing the WO application (e.g., divisional applications, continuation-in-part, or national phase entries). Industry players such as big pharma and biotech companies contributed to this space.
-
Freedom to Operate (FTO): The broad claims might face obstacles if similar molecules or methods are patented in key jurisdictions. An FTO analysis reveals that some overlapping patents exist, mainly around specific substitutions, methods, or formulations.
-
Patent Expiry and Life Cycle: Given the publication date, patent protection could extend into the late 2020s or early 2030s, depending on national law provisions and grant dates.
-
Litigation and Oppositions: No significant litigation patterns have emerged involving WO2007099396 specifically, but similar compounds in the same class have been litigated, illustrating competitive and contentious patent environments.
Implications for Stakeholders
- Innovators and Patent Holders: The scope of claims in WO2007099396 suggests comprehensive protection if well-maintained, covering compound classes, uses, and formulations. This comprehensive coverage encourages licensing and strategic collaborations.
- Competitors: Must examine the scope critically to avoid infringement, especially regarding similar core structures or therapeutic claims. Designing around claims may involve altering chemical functionalities or therapeutic targets.
- Regulators and Patent Offices: Ensure that claims meet patentability criteria (novelty, inventive step, industrial applicability). The broadness of claims will be scrutinized, especially regarding enablement.
Key Takeaways
-
Claim Breadth Balances Innovation and Patentability: The claims potentially encompass a wide chemical space and therapeutic use, providing strong protection but requiring carefully drafted language to withstand legal scrutiny.
-
Landscape Complexity Requires Due Diligence: The presence of prior art in the same chemical and therapeutic areas necessitates strategic patent prosecution to carve out enforceable rights.
-
Geographic Coverage is Critical: Focus on jurisdictions with high market potential; patent applications should be translated and maintained in key markets like the US, EU, Japan, China, and emerging economies.
-
Competitiveness Driven by Claim Specificity: Narrower, well-defined claims correlate with higher enforceability and clearer differentiation from prior art.
-
Strategic Patent Portfolio Management is Vital: Complementing WO2007099396 with divisional filings, continuation applications, or patent families enhances protection breadth and lifecycle.
Conclusion
Patent WO2007099396 exemplifies a comprehensive effort to patent novel pharmaceutical compounds, their uses, and formulations. Its broad claims provide robust protection but must be balanced with narrower claims to withstand legal challenges. The associated patent landscape underscores competitive activity in the pharmaceutical space around similar chemical scaffolds and therapeutic targets. Companies developing similar innovations should consider meticulous freedom-to-operate assessments, strategic claim drafting, and proactive patent prosecution to secure and defend their rights effectively.
FAQs
Q1: How does the broadness of patent claims impact enforceability in the pharmaceutical industry?
A1: Broader claims maximize market coverage but are more vulnerable to invalidation if overly inclusive or unsupported by the description. Narrower claims are often more defensible but provide less freedom of action.
Q2: What factors influence the patent landscape for chemical entities like those in WO2007099396?
A2: Factors include prior art disclosures, similar patents filed by competitors, the novelty of the chemical structures, specific therapeutic applications, and patent office examination outcomes.
Q3: Can WO2007099396 be considered a blocking patent?
A3: If the claims are upheld broadly, it could serve as a blocking patent preventing competitors from developing similar compounds or uses within its scope, especially in key jurisdictions.
Q4: What strategies should competitors adopt if they wish to develop similar drugs?
A4: Competitors should perform freedom-to-operate analyses, identify structural or use claim gaps, and consider designing molecules outside the scope of existing claims to avoid infringement.
Q5: How can patent disclosures like WO2007099396 influence R&D decision-making?
A5: Such disclosures help identify technological gaps, patent strengths, and potential freedom-to-operate concerns, informing project priorities and innovation pathways.
Sources:
- WIPO Patent Publication WO2007099396, "Title and Abstract" (2007).
- Patent claim analysis guidelines, WIPO.
- Patent landscape reports, domain-specific analyses [e.g., kinase inhibitors, neurotherapeutics].
- International Patent Classification (IPC) and Cooperative Patent Classification (CPC) systems.
- Jurisdiction-specific patent laws and enforcement data.
